SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-039843
Filing Date
2023-08-08
Accepted
2023-08-08 16:17:10
Documents
14
Period of Report
2023-08-08
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K janx-20230808.htm   iXBRL 8-K 64652
2 EX-99.1 janx-ex99_1.htm EX-99.1 244131
3 GRAPHIC img201480580_0.jpg GRAPHIC 4603
  Complete submission text file 0000950170-23-039843.txt   453830

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT janx-20230808_pre.xml EX-101.PRE 11945
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT janx-20230808.xsd EX-101.SCH 2461
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT janx-20230808_lab.xml EX-101.LAB 15567
8 EXTRACTED XBRL INSTANCE DOCUMENT janx-20230808_htm.xml XML 4898
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

IRS No.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40475 | Film No.: 231151601
SIC: 2834 Pharmaceutical Preparations